Duality Advisers, LP Vertex Pharmaceuticals Inc Transaction History

Duality Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 02, 2022	SELL	$177.01 - $223.45 $597,585 - $754,367	-3,376 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$181.39 - $202.99 $348,268 - $389,740	-1,920 Reduced 36.25%	3,376 $612,000
Q2 2021 Aug 09, 2021	SELL	$187.49 - $221.1 $951,324 - $1.12 Million	-5,074 Reduced 48.93%	5,296 $1.07 Million
Q1 2021 May 13, 2021	SELL	$207.02 - $241.31 $1.24 Million - $1.44 Million	-5,988 Reduced 36.61%	10,370 $2.23 Million
Q4 2020 Feb 09, 2021	BUY	$207.01 - $276.09 $2.61 Million - $3.48 Million	12,598 Added 335.05%	16,358 $3.87 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $96,635 - $114,571	378 Added 11.18%	3,760 $1.02 Million
Q2 2020 Jul 29, 2020	BUY	$225.48 - $295.8 $762,573 - $1 Million	3,382 New	3,382 $981,000
Q1 2020 May 06, 2020	SELL	$199.77 - $247.81 $8.24 Million - $10.2 Million	-41,254 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$166.71 - $223.91 $6.49 Million - $8.71 Million	38,904 Added 1655.49%	41,254 $9.03 Million
Q3 2019 Nov 08, 2019	BUY	$166.23 - $187.09 $390,640 - $439,661	2,350 New	2,350 $398,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.